非转移性乳腺癌患者停用地舒单抗后:下一步怎么办?
该叙述性综述由国际骨质疏松基金会科学顾问委员会癌症诱导骨病工作组完成,检索2006年至2025年8月PubMed文献共126篇,聚焦接受芳香化酶抑制剂(AI)治疗的早期乳腺癌患者使用地舒单抗的抗骨吸收与抗骨折获益、停药后反跳现象相关骨折风险及干预措施。专家共识建议地舒单抗停药后启动双膦酸盐治疗,但目前无最优方案。
要点
- AI治疗加速骨丢失并增加骨折风险,地舒单抗或双膦酸盐用于预防。
- 地舒单抗停药后骨转换增加,可能出现自发性反跳相关椎体骨折。
- 专家共识建议停用地舒单抗后启动双膦酸盐,但无最优方案。
核心结论
- 地舒单抗对接受AI治疗的早期乳腺癌患者具有抗骨吸收和抗骨折获益,但停药后存在反跳相关椎体骨折风险,专家共识建议停药后启动双膦酸盐治疗。
研究设计与样本
- 国际骨质疏松基金会科学顾问委员会癌症诱导骨病工作组开展的叙述性综述,通过PubMed检索2006年至2025年8月文献,纳入126篇密切 related 论文。
主要发现
- AI治疗导致骨丢失加速和骨折风险增加。
- 地舒单抗停药后骨转换增加,即使无其他骨脆性危险因素,也可能发生自发性反跳相关椎体骨折。
关键数值与推荐
- 专家共识建议地舒单抗停药后启动双膦酸盐治疗,但目前无最优双膦酸盐方案。
临床怎么用
- 对接受AI治疗的早期乳腺癌患者,应关注地舒单抗停药后的反跳现象,并按专家共识在停药后启动双膦酸盐治疗。
局限性
- 本文为叙述性综述,且目前无最优双膦酸盐方案,诸多开放研究问题需未来前瞻性研究回答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aromatase inhibitors (AIs) are one of the adjuvant endocrine therapies of choice, for estrogen receptor-positive breast cancer in postmenopausal women and premenopausal women with ovarian suppression. However, treatment with AIs leads to accelerated bone loss, and an increased fracture risk. Denosumab or bisphosphonates are recommended to prevent bone loss and reduce fracture risk during AIs treatment. However, specific attention must be paid to the "rebound phenomenon" after denosumab discontinuation. This review focuses on the therapeutic benefits of denosumab for its antiresorptive and antifracture effect in women with early breast cancer treated with AIs, risks related to denosumab discontinuation after treatment with AIs, prevention, and potential interventions for its associated fracture risk. A narrative review of available literature was carried out by International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease. Papers were retrieved by means of a PubMed enquiry (from 2006 to August 2025). A total of 126 papers closely related to our topic were included. After denosumab withdrawal in women with breast cancer treated with AIs, bone turnover increases, and there is a risk of spontaneous rebound-associated vertebral fractures, even in the absence of other risk factors for bone fragility. Therefore, expert consensus suggests initiating bisphosphonate treatment after denosumab discontinuation, even though there is no an optimal bisphosphonate regimen. There are numerous open research questions which future prospective studies will have to answer in order to personalize the most appropriate antiresorptive therapy for each patient.
引用
- Marcucci G, Biver E, Body JJ, et al. Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next? Osteoporos Int. 2026. PMID: 41524787. doi:10.1007/s00198-025-07798-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。